Brian Kelly, President of Clinical Healthcare Solutions at Ascend Learning, Joins Catasys in New Senior Executive Vice Presid...
March 03 2020 - 8:30AM
Business Wire
Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the
“Company”), a leading AI and technology-enabled healthcare company,
today announced the appointment of Mr. Brian Kelly to the newly
created position of Senior Executive Vice President, Product
Portfolio. Mr. Kelly will report to Mr. Curt Medeiros who joined
Catasys as President and COO in December 2019.
Mr. Terren Peizer, Chairman and CEO of Catasys, stated, “Over
the last year, we have added senior healthcare industry executives
to our Board of Directors to help guide us through the tremendous
growth we expect in 2020 and beyond. Similarly, for Catasys to be
able to capitalize on this immense industry opportunity, it was
vital that we add senior executives with a proven track record of
scaling businesses with hundreds of millions in revenues at the
minimum. We began that process with the appointment of Curt
Medeiros as President and COO in late 2019. Brian Kelly is a proven
leader of similar stature. We will continue to build out our senior
management team to deliver robust revenue growth for years to
come.”
“Our nationwide commitment to improving the health and saving
the lives of those who consciously or unconsciously avoid care
requires continuous innovation and the integration of Catasys’
proprietary AI capabilities into new evidence-based programs at the
intersection of behavioral health and chronic disease. As we embark
on a rapid growth trajectory in 2020 and scale Catasys programs to
broader populations, we are delighted that Brian is joining our
leadership team as Senior Executive Vice President, Product
Portfolio. Brian’s executive leadership experience, strong growth
orientation, and in-depth knowledge of healthcare data and
analytics will be valuable as we look to accelerate the
company-wide innovation initiatives that we have planned in the
near and long term.”
Mr. Kelly brings 25 years of healthcare experience to his new
role at Catasys, from Big Pharma and medical devices, to healthcare
data and analytics. He joins the Company from the Clinical
Healthcare Solutions business at Ascend Learning, where he was
President of Ascend Learning’s largest group and oversaw six
businesses: ATI Nursing Education, Nursing CE, MedHub, National
Health Career Association, BoardVitals and Kognito. Previously Mr.
Kelly was President of Optum’s Life Sciences business at
UnitedHealth Group, serving clients globally and driving client
value through best in class real-world data and analytics. At
Dupont and Merck, Mr. Kelly acquired executive experience in
research and development, strategy, and general management. His
career began as an active-duty Naval officer. He holds a master’s
degree in Management from the University of Pennsylvania (Wharton
and SEAS) and a bachelor’s degree in Chemical Engineering from
Drexel University.
Mr. Medeiros stated, “Brian’s leadership experience at Ascend
Learning, Optum, Merck, and Dupont make him uniquely qualified to
lead our product portfolio strategy and advance the analytic
capabilities and value of Catasys PRETM (Predict-Recommend-Engage),
so that our market-leading care community of coaches, member
engagement specialists and community coordinators can serve even
more members in ways that closely integrate with the programs of
our Health Plan customers, improve member health and save more
lives.”
About Catasys, Inc.
Catasys, Inc. is a leading AI and technology-enabled healthcare
company whose mission is to help improve the health and save the
lives of as many people as possible. Its Catasys PRETM
(Predict-Recommend-Engage) platform predicts people whose chronic
disease will improve with behavior change, recommends effective
care pathways that people are willing to follow, and engages people
who aren’t getting the care they need. By combining predictive
analytics with human engagement, Catasys delivers improved member
health and validated outcomes and savings to healthcare payers.
Catasys’ integrated, technology-enabled OnTrak solution, a
critical component of the Catasys PRE platform, is designed to
treat members with behavioral conditions that cause or exacerbate
chronic medical conditions such as diabetes, hypertension, coronary
artery disease, COPD, and congestive heart failure, which result in
high medical costs.
Catasys has a unique ability to engage these members, who do not
otherwise seek behavioral healthcare, leveraging proprietary
enrollment capabilities built on deep insights into the drivers of
care avoidance.
OnTrak integrates evidence-based psychosocial and medical
interventions delivered either in-person or via telehealth, along
with care coaching and in-market Community Care Coordinators who
address the social and environmental determinants of health,
including loneliness. The program improves member health and
delivers validated cost savings to healthcare payers of more than
50 percent for enrolled members. OnTrak is available to members of
leading national and regional health plans in 28 states and in
Washington, D.C.
Learn more at www.catasys.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed
in this press release are forward-looking and made pursuant to the
Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many
of which are beyond our control, which may cause actual results to
differ materially from stated expectations. These risk factors
include, among others, changes in regulations or issuance of new
regulations or interpretations, limited operating history, our
inability to execute our business plan, increase our revenue and
achieve profitability, lower than anticipated eligible members
under our contracts, our inability to recognize revenue, lack of
outcomes and statistically significant formal research studies,
difficulty enrolling new members and maintaining existing members
in our programs, the risk that treatment programs might not be
effective, difficulty in developing, exploiting and protecting
proprietary technologies, intense competition and substantial
regulation in the health care industry, the risks associated with
the adequacy of our existing cash resources and our ability to
continue as a going concern, our ability to raise additional
capital when needed and our liquidity. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plan," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties we
face, please refer to our most recent Securities and Exchange
Commission filings which are available on its website at
http://www.sec.gov. Such forward-looking statements are current
only as of the date they are made, and we assume no obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200303005296/en/
Catasys, Inc. Ariel Davis Phone: 310-444-4346 Email:
ariel@catasys.com
Catasys (NASDAQ:CATS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Catasys (NASDAQ:CATS)
Historical Stock Chart
From Jul 2023 to Jul 2024